Guizhou Sanli Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceuticals. The products primarily include respiratory medications, tonics, gynecological medications, orthopedic medications, and cardiovascular medications. The specific pharmaceutical products include Kaihoujian Spray (children's version), Kaihoujian Spray, Qijiao Shengbai Capsules, Fuke Zaizao Pills, Zhike Huatan Pills, Huangqi Granules, and Qiangli Tianma Duzhong Capsules. The Company distributes its products within the domestic market.

Employees

1,887

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
22/06/26	CN¥15.43	-1.34%	17,833,200
18/06/26	CN¥15.64	+3.30%	19,687,200
17/06/26	CN¥15.14	-1.30%	14,246,200
16/06/26	CN¥15.34	+4.07%	15,276,300

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 22/06/2026			5-day change	1st Jan Change
15.43 ^CNY	-1.34%		+4.68%	+31.88%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE

Market Cap	6.25B 922M 806M 745M 696M 1.31B 87.13B 1.32B 8.86B 3.45B 42.84B 3.46B 3.39B 149B	P/E 2024	19.4x	P/E 2025	106x
Enterprise Value	6.59B 973M 851M 787M 734M 1.38B 91.99B 1.39B 9.35B 3.64B 45.23B 3.65B 3.58B 157B	EV / Sales 2024	2.48x	EV / Sales 2025	2.99x
Free-Float	40.74%	Yield 2024	2.62%	Yield 2025	0.51%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE
05-25	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 700 million in funding	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 300 million in funding	CI
12-03	Sanli Pharma to Withdraw Stake in Associate; Shares Down 3%	MT
27/10/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
12/09/25	Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on September 13, 2024.	CI
11/09/25	Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on September 12, 2024, has closed with 7,869,300 shares, representing 1.93% for CNY 99.95 million.	CI
27/08/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
23/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 26, 2025	CI
22/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	-1.34%
1 week	+4.68%
Current month	-5.22%
1 month	+7.98%
3 months	+39.64%
6 months	+30.54%
Current year	+31.88%

GuiZhou SanLi Pharmaceutical Co.,Ltd Stock

Stocks

603439

CNE1000040B4

Pharmaceuticals

Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd

Chart: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest news : GuiZhou SanLi Pharmaceutical Co.,Ltd

Quotes and Performance

Course Extremes

Managers and Directors: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	14.7	16.25
1 month	13.41	17.46
Current year	10.49	17.46
1 year	10.49	17.46
3 years	10.49	20.34
5 years	10.49	21.28
10 years	8.82	44.1

Manager	Title	Age	Since
Qian Fan Zhang CEO	Chief Executive Officer	41	27/05/2024
Hai Zhang CEO	Chief Executive Officer	41	01/09/2011
Ke Guo DFI	Director of Finance/CFO	39	01/11/2024

Director	Title	Age	Since
Hai Zhang CHM	Chairman	41	01/03/2018
Qian Fan Zhang BRD	Director/Board Member	41	01/03/2018
Yong Jian Sheng BRD	Director/Board Member	52	28/01/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/09/24	Hai Zhang	Sell	Chief Executive Officer	21,000,000	5.1428%
02/08/24	Jue Ben Wang	Buy	Director	13,000	0.0032%
05/08/23	Yuan Yu	Sell		25,000	0.0061%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	-1.34%	+4.68%	+31.54%	-6.43%	922M
ELI LILLY AND COMPANY	+0.32%	-2.41%	+44.49%	+140.80%	983B
JOHNSON & JOHNSON	+1.27%	-1.85%	+54.41%	+39.65%	557B
ABBVIE INC.	+6.25%	+3.80%	+24.13%	+67.39%	406B
ROCHE HOLDING AG	+1.25%	-1.93%	+23.33%	+16.35%	314B
ASTRAZENECA PLC	+1.76%	+1.69%	+29.64%	+18.26%	273B
NOVARTIS AG	+1.60%	+1.95%	+28.36%	+34.57%	272B
NOVO NORDISK A/S	+2.32%	+9.42%	-31.94%	-43.64%	203B
AMGEN INC.	+2.11%	-1.66%	+19.14%	+50.10%	186B
GILEAD SCIENCES, INC.	+0.90%	+0.46%	+15.09%	+59.86%	155B
Average	+1.16%	-0.36%	+23.82%	+37.69%	335.13B
Weighted average by Cap.	+1.15%	-2.21%	+31.75%	+64.78%

	2024	2025
Net sales	2.14B 317M 277M 256M 239M 448M 29.92B 452M 3.04B 1.18B 14.71B 1.19B 1.16B 51.1B	1.7B 251M 220M 203M 190M 356M 23.76B 359M 2.41B 939M 11.68B 944M 923M 40.58B
Net income	274M 40.46M 35.35M 32.7M 30.52M 57.29M 3.82B 57.71M 389M 151M 1.88B 152M 149M 6.53B	46.25M 6.83M 5.97M 5.52M 5.15M 9.67M 645M 9.74M 65.59M 25.52M 317M 25.64M 25.08M 1.1B
Net Debt	108M 15.9M 13.89M 12.85M 11.99M 22.51M 1.5B 22.68M 153M 59.4M 739M 59.68M 58.38M 2.57B	349M 51.48M 44.98M 41.61M 38.84M 72.91M 4.87B 73.44M 494M 192M 2.39B 193M 189M 8.31B